How to buy Vir Biotechnology stock | $61.83

Vir Biotechnology, Inc is a biotechnology business based in the US. Vir Biotechnology shares (VIR) are listed on the NASDAQ and all prices are listed in US Dollars. Vir Biotechnology employs 327 staff and has a trailing 12-month revenue of around 0.00.

Vir Biotechnology share price

Use our graph to track the performance of VIR stocks over time.

Vir Biotechnology shares at a glance

• Key figures

Information last updated 2021-05-11.

Latest market close	$61.83
52-week range	$25.31 - $83.50
50-day moving average	$47.58
200-day moving average	$44.09
Wall St. target price	$88.40
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-5.76

Buy Vir Biotechnology shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Vir Biotechnology stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Vir Biotechnology, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vir Biotechnology price performance over time

Historical closes compared with the close of $61.83 from 2021-03-11

1 week (2021-05-07)	43.89%
1 month (2021-04-15)	37.28%
3 months (2021-02-13)	N/A
6 months (2020-11-13)	129.17%

1 year (2020-05-15)	103.72%
2 years (2019-05-13)	N/A
3 years (2018-05-13)	N/A
5 years (2016-05-13)	N/A

Vir Biotechnology financials

Revenue TTM	$76.4 million
Gross profit TTM	$-196,511,000
Return on assets TTM	-23.37%
Return on equity TTM	-52.36%
Profit margin	0%
Book value	N/A
Market capitalisation	$5 billion

TTM: trailing 12 months

Shorting Vir Biotechnology shares

There are currently 8.2 million Vir Biotechnology shares held short by investors – that's known as Vir Biotechnology's "short interest". This figure is 4.1% up from 7.9 million last month.

There are a few different ways that this level of interest in shorting Vir Biotechnology shares can be evaluated.

Vir Biotechnology's "short interest ratio" (SIR)

Vir Biotechnology's "short interest ratio" (SIR) is the quantity of Vir Biotechnology shares currently shorted divided by the average quantity of Vir Biotechnology shares traded daily (recently around 815153.66336634). Vir Biotechnology's SIR currently stands at 10.1. In other words for every 100,000 Vir Biotechnology shares traded daily on the market, roughly 10100 shares are currently held short.

However Vir Biotechnology's short interest can also be evaluated against the total number of Vir Biotechnology shares, or, against the total number of tradable Vir Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vir Biotechnology's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Vir Biotechnology shares in existence, roughly 60 shares are currently held short) or 0.1198% of the tradable shares (for every 100,000 tradable Vir Biotechnology shares, roughly 120 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Vir Biotechnology.

Find out more about how you can short Vir Biotechnology stock.

Vir Biotechnology share dividends

We're not expecting Vir Biotechnology to pay a dividend over the next 12 months.

Vir Biotechnology overview

Vir Biotechnology, Inc. , a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc. ; a collaboration, license, and option agreement with Visterra, Inc. ; license agreements with The Rockefeller University and MedImmune, Inc. ; a collaboration with WuXi Biologics; and a collaborative research agreement with Generation Bio.

Frequently asked questions

• What percentage of Vir Biotechnology is owned by insiders or institutions?

  Currently 13.869% of Vir Biotechnology shares are held by insiders and 80.948% by institutions.

• How many people work for Vir Biotechnology?

  Latest data suggests 327 work at Vir Biotechnology.

• When does the fiscal year end for Vir Biotechnology?

  Vir Biotechnology's fiscal year ends in December.

• Where is Vir Biotechnology based?

  Vir Biotechnology's address is: 499 Illinois Street, San Francisco, CA, United States, 94158

• What is Vir Biotechnology's ISIN number?

  Vir Biotechnology's international securities identification number is: US92764N1028

• What is Vir Biotechnology's CUSIP number?

  Vir Biotechnology's Committee on Uniform Securities Identification Procedures number is: 92764N102